Spyre Therapeutics, Inc. SYRE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$69.01M-10.4% | -$62.53M-459% | -$11.18M+69.5% | -$36.72M+18.0% | -$44.77M+20.5% | ||
| $12.81M+30.5% | $9.81M+2.6% | $9.57M+2.0% | $9.38M+5.9% | $8.86M-3.9% | ||
| -$57.37M-28.7% | -$44.58M-20.1% | -$37.12M+20.3% | -$46.56M-13.6% | -$40.99M-10.2% | ||
| $56.58M+123% | -$247.41M-1,090% | $25M-68.4% | $79M+129,605% | -$61K+100.0% | ||
| $12.26M-96.1% | $312.81M+6,837% | -$4.64M-735% | $731K+485% | $125K-99.9% | ||
| $11.46M— | —— | -$16.76M— | —— | -$40.93M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Spyre Therapeutics, Inc. generate?
- Spyre Therapeutics, Inc. (SYRE) generated -$185.6M in operating cash flow over the trailing twelve months.
- Where does Spyre Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.